MXPA03005526A - Antagonistas ccr5 y polipeptido dp-178 para el tratamiento de infecciones virales. - Google Patents

Antagonistas ccr5 y polipeptido dp-178 para el tratamiento de infecciones virales.

Info

Publication number
MXPA03005526A
MXPA03005526A MXPA03005526A MXPA03005526A MXPA03005526A MX PA03005526 A MXPA03005526 A MX PA03005526A MX PA03005526 A MXPA03005526 A MX PA03005526A MX PA03005526 A MXPA03005526 A MX PA03005526A MX PA03005526 A MXPA03005526 A MX PA03005526A
Authority
MX
Mexico
Prior art keywords
viral infections
combination method
treating viral
treating
combination
Prior art date
Application number
MXPA03005526A
Other languages
English (en)
Spanish (es)
Inventor
M Baroudy Bahige
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA03005526A publication Critical patent/MXPA03005526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
MXPA03005526A 2000-12-19 2001-12-17 Antagonistas ccr5 y polipeptido dp-178 para el tratamiento de infecciones virales. MXPA03005526A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25665700P 2000-12-19 2000-12-19
PCT/US2001/048802 WO2002056902A2 (en) 2000-12-19 2001-12-17 Ccr5 antagonist and dp-178 polypeptide for treating viral infections

Publications (1)

Publication Number Publication Date
MXPA03005526A true MXPA03005526A (es) 2003-10-06

Family

ID=22973061

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005526A MXPA03005526A (es) 2000-12-19 2001-12-17 Antagonistas ccr5 y polipeptido dp-178 para el tratamiento de infecciones virales.

Country Status (12)

Country Link
US (1) US20050065319A1 (cg-RX-API-DMAC10.html)
EP (1) EP1385534A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005500981A (cg-RX-API-DMAC10.html)
CN (1) CN1481251A (cg-RX-API-DMAC10.html)
AR (1) AR031931A1 (cg-RX-API-DMAC10.html)
BR (1) BR0116253A (cg-RX-API-DMAC10.html)
CA (1) CA2431919A1 (cg-RX-API-DMAC10.html)
HU (1) HUP0302241A3 (cg-RX-API-DMAC10.html)
MX (1) MXPA03005526A (cg-RX-API-DMAC10.html)
NO (1) NO20032769L (cg-RX-API-DMAC10.html)
WO (1) WO2002056902A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200304560B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
RU2353357C2 (ru) * 2003-05-16 2009-04-27 Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют Композиции для супрессии экспрессии ccr5 и способы их применения
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
JP2009517474A (ja) * 2005-11-30 2009-04-30 シェーリング コーポレイション Ccr5拮抗剤およびcxcr4拮抗剤の組み合わせを含む組成物
WO2007065007A2 (en) * 2005-12-01 2007-06-07 Government Of The U.S.A., As Repersented By The Secretary, Dept. Of Health And Human Services Treatment of viral infections
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
CN104039815A (zh) * 2012-02-28 2014-09-10 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CN1192688A (zh) * 1995-06-07 1998-09-09 特莱默里斯公司 联合疗法治疗hiv和其它病毒性感染
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PL203117B1 (pl) * 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
WO2000066141A2 (en) * 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Also Published As

Publication number Publication date
EP1385534A2 (en) 2004-02-04
WO2002056902A2 (en) 2002-07-25
BR0116253A (pt) 2006-05-02
WO2002056902A3 (en) 2002-12-05
HUP0302241A3 (en) 2005-06-28
JP2005500981A (ja) 2005-01-13
ZA200304560B (en) 2005-07-27
NO20032769D0 (no) 2003-06-18
US20050065319A1 (en) 2005-03-24
CA2431919A1 (en) 2002-07-25
CN1481251A (zh) 2004-03-10
NO20032769L (no) 2003-08-18
HUP0302241A2 (hu) 2003-11-28
AR031931A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
EP1128832A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES
MXPA03002410A (es) 4-amino-quinazolinas.
ZA200210206B (en) Expression system.
ZA200209047B (en) Process for permanently reshaping the hair using particular aminosilicones.
ZA200300447B (en) Granulation process.
MXPA02000893A (es) Pasteurizador.
MXPA03004401A (es) Metodos y dispositivos para tratar problemas de tartamudez.
EG23262A (en) Delta -pyrrolines.
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
MXPA03001710A (es) Metodo de limpieza.
AP2004002968A0 (en) Single dose azithromycin for treating respiratory infections.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
ZA200306040B (en) Hepatitis B virus treatment.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03003347A (es) Procedimiento para purificacion de pravastatina.
MXPA03002411A (es) 4-amino-quinazolinas.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA01010008A (es) Metodos para promover la piel clara.
MXPA03005569A (es) PROCEDIMIENTO MEJORADO PARA LA PREPARACION DE UN FARMACO ANTIMIGRAnOSO.
MXPA03002521A (es) Triazol-epotilona.
NO20032769L (no) Kombinasjonsmetode for behandling av virale infeksjoner
GB0123898D0 (en) Method for treating objects